Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 21% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 21% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $61.7M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 7
- Hold 9
- Sell 1
Today's price within the analysts' price targets
The average target of $13.4 is 45% above today's price. 41% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Global Spine 100%
By region
- Other Countries 61%
- ITALY 18%
- FRANCE 9.6%
- GERMANY 7.3%
- BRAZIL 3.9%
Global Spine brings in 100% of revenue.
Segments in detail